We've just received notice that our review paper, which summarises the work we have been doing for the last 7 years, is accepted by Frontiers in Thyroid Endocrinology. Its abstract is now available at:
Frontiers in Thyroid Endocrinology
MINI REVIEW ARTICLE
Provisionally accepted The full-text will be published soon (I expect around mid January).
Front. Endocrinol. | doi: 10.3389/fendo.2017.00364
Minireview: Recent Advances in Thyroid Hormone Regulation: Towards a New Paradigm for Optimal Diagnosis and Treatment
Rudolf Hoermann*, John E. Midgley, Rolf Larisch and Johannes W. Dietrich
The whole paper shows a) in control and expression of thyroid activity everyone is an individual - so that mere placement of values in or out of range is not diagnostically helpful or appropriate. b) TSH is unsuitable for monitoring thyroid hormone therapy, especially T4-only. All parameters TSH, FT4 and FT3 must be used in diagnosis c) the response of a person to thyroid dysfunction is unique and needs therefore unique individual treatment and control of treatment modalities. d) all Randomized Clinical Trials attempting to assess i) preferences for combined T4-T3 treatment over T4-only, and ii) those trying to show correlations between suppressed TSH and atrial fibrillation and osteoporosis are as a class wrongly devised and cannot demonstrate satisfactorily the phenomena they are studying. This comes about from a statistical error that all the studies have made in using nonselection in choosing their patient panels. I hope the paper will be strong ammunition for change in the upcoming review of NICE guidelines on thyroid treatment.